<div id="readability-page-1"><div>Barinthus Biotherapeutics Investor Alert: Kahn Swick &amp; Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick &amp; Foti, LLC (“KSF”) are investigating the proposed merger of Barinthus Biotherapeutics plc (the “Company”) (NasdaqGM: BRNS) and Clywedog Therapeutics, Inc. Upon consummation of the transaction, Barinthus shareholders will own only 34.33% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to Barinthus shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgm-brns/ to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn <img src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTE3NTUyNDdyMQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" original-src="https://imageproxy.pbkrs.com/https://cts.businesswire.com/ct/CT/query-ZGlzdHJvPW54JmlkPWJ3bmV3cyZsYW5nPWVuJnNpZD1tc3RyMyZzdHk9MjAyNjA1MTE3NTUyNDdyMQ"/> Kahn Swick &amp; Foti, LLC Lewis Kahn, Managing Partner lewis.kahn@ksfcounsel.com 855-768-1857 1100 Poydras St., Suite 960 New Orleans, LA 70163 View source version on businesswire.com: https://www.businesswire.com/news/home/20260511755247/en/</div></div>

BRNS

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

2 倍做多纳斯达克生物技术 ETF - ProShares

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

IBBQ

纽交所高增长板生物技术指数 ETF - First Trust

Kahn Swick & Foti, LLC 正在调查 Barinthus Biotherapeutics plc（纳斯达克代码：BRNS）与 Clywedog Therapeutics, Inc. 之间的拟议合并。合并后，Barinthus 的股东将仅持有新实体的 34.33%。该公司旨在评估合并过程对 Barinthus 股东的公平性和充分性。感兴趣的各方可以联系 KSF 管理合伙人 Lewis S. Kahn，获取有关与该交易相关的法律权利的更多信息

Barinthus Biotherapeutics Investor Alert: Kahn Swick & Foti, LLC Investigates Merger of Barinthus Biotherapeutics plc - BRNS

MorningStar

Barinthus Biotherapeutics

Invesco Nasdaq Biotechnology ETF

Barinthus Biotherapeutics 投资者警报：Kahn Swick & Foti, LLC 正在调查 Barinthus Biotherapeutics plc 的合并 - BRNS